MedTrace Logo

RT201(Tumor Antigen-specific Macrophage Tumor Vaccine)

NCT05930301 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2023-07-05

No results posted yet for this study

Summary

This clinical study will include tumor patients in strict accordance with the inclusion and exclusion criteria set in this clinical study, and carry out tumor-specific antigen screening, HLA typing, blood sample collection, cell separation, cell culture and cell reinfusion according to the SOP of Suzhou Ruotai RT201 Cell Therapy. According to the efficacy evaluation criteria set in this clinical study, the included patients will be evaluated and followed up for a long time, and the original data will be saved to provide real and effective clinical data for the safety and efficacy of RT201 tumor single-target individualized clinical treatment.

Conditions

  • Cervical

Sponsors & Collaborators

  • Suzhou Royaltechmed Co.,Ltd.

    collaborator UNKNOWN

  • Peihua Lu

    lead OTHER

Principal Investigators

  • Peihua Lu, doctor · Self

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2024-10-01
Completion
2024-12-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05930301 on ClinicalTrials.gov